Yongjun Han
Yongjun Han has a total of 17 co-authors. Here are the top co-authors by number of shared publications:
- Jiangpeng Wei
Department of Digestive Surgery, Xijing Hospital of Digestive Diseases, The First Affiliated Hospital of Fourth Military Medical University (Xijing Hospital), Fourth Military Medical University, Xi'an, China
2 shared publications - Li-Di Xu
Genecast Biotechnol Co Ltd, Wuxi, Peoples R China
2 shared publications - Ning Shen
Genecast Biotechnology Co, Ltd, Wuxi, Jiangsu, China
2 shared publications - Rui Qi Gao
Xijing Hospital
2 shared publications - Weidong Wang
Air Force Mil Med Univ, Xijing Hosp, Dept Gastrointestinal Surg, 127 Changle West Rd, Xian 710033, Shaanxi, Peoples R China
2 shared publications - Weizhi Chen
Genecast Biotechnology Co., Ltd, Wuxi, China
2 shared publications
Latest Publications
- Open Access
- 20 September 2023
- Published by JMIR Publications Inc. in JMIR Research Protocols
- Vol. 12 (1) , e48247
Multidimensional Analysis of a Cell-Free DNA Whole Methylome Sequencing Assay for Early Detection of Gastric Cancer: Protocol for an Observational Case-Control Study
Background: Commonly used noninvasive serological indicators serve as a step before endoscope diagnosis and help identify the high-risk gastric cancer (GC) population. However, they are associated with high false positives and high false negatives. Alternative noninvasive approaches, such as cancer-related features in cell-free DNA (cfDNA) fragments, have been gradually identified and play essential roles in early cancer detection. The integrated analysis of multiple cfDNA features has enhanced detection sensitivity compared to individual features. Objective: This study aimed to develop and validate an assay based on assessing genomic-scale methylation and fragmentation profiles of plasma cfDNA for early cancer detection, thereby facilitating the early diagnosis of GC. The primary objective is to evaluate the overall specificity and sensitivity of the assay in predicting GC within the entire cohort, and subsequently within each clinical stage of GC. The secondary objective involved investigating the specificity and sensitivity of the assay in combination with possible serological indicators. Methods: This is an observational case-control study. Blood samples will be prospectively collected before gastroscopy from 180 patients with GC and 180 nonmalignant control subjects (healthy or with benign gastric diseases). Cases and controls will be randomly divided into a training and a testing data set at a ratio of 2:1. Plasma cfDNA will be isolated and extracted, followed by bisulfite-free low-depth whole methylome sequencing. A multidimensional model named Thorough Epigenetic Marker Integration Solution (THEMIS) will be constructed in the training data set. The model includes features such as the methylated fragment ratio, chromosomal aneuploidy of featured fragments, fragment size index, and fragment end motif. The performance of the model in distinguishing between patients with cancer and noncancer controls will then be evaluated in the testing data set. Furthermore, GC-related biomarkers, such as pepsinogen, gastrin-17, and Helicobacter pylori, will be measured for each patient, and their predictive accuracy will be assessed both independently and in combination with the THEMIS model Results: Recruitment began in November 2022 and will be ended in April 2024. As of August 2022,250 patients have been enrolled. The final data analysis is anticipated to be completed by September 2024. Conclusions: This is the first registered case-control study designed to investigate a stacked ensemble model integrating several cfDNA features generated from a bisulfite-free whole methylome sequencing assay. These features include methylation patterns, fragmentation profiles, and chromosomal copy number changes, with the aim of identifying the GC population. This study will determine whether multidimensional analysis of cfDNA will prove to be an effective strategy for distinguishing patients with GC from nonmalignant individuals within the Chinese population. We anticipate the THEMIS model will complement the standard-of-care screening and aid in identifying high-risk patients for further diagnosis. Trial Registration: ClinicalTrial.gov NCT05668910; https://www.clinicaltrials.gov/study/NCT05668910
- 20 September 2023
- Published by JMIR Publications Inc. in JMIR Research Protocols
- Vol. 12 (1) , e48247
Open AccessMultidimensional Analysis of a Cell-Free DNA Whole Methylome Sequencing Assay for Early Detection of Gastric Cancer: Protocol for an Observational Case-Control Study
Background: Commonly used noninvasive serological indicators serve as a step before endoscope diagnosis and help identify the high-risk gastric cancer (GC) population. However, they are associated with high false positives and high false negatives. Alternative noninvasive approaches, such as cancer-related features in cell-free DNA (cfDNA) fragments, have been gradually identified and play essential roles in early cancer detection. The integrated analysis of multiple cfDNA features has enhanced detection sensitivity compared to individual features. Objective: This study aimed to develop and validate an assay based on assessing genomic-scale methylation and fragmentation profiles of plasma cfDNA for early cancer detection, thereby facilitating the early diagnosis of GC. The primary objective is to evaluate the overall specificity and sensitivity of the assay in predicting GC within the entire cohort, and subsequently within each clinical stage of GC. The secondary objective involved investigating the specificity and sensitivity of the assay in combination with possible serological indicators. Methods: This is an observational case-control study. Blood samples will be prospectively collected before gastroscopy from 180 patients with GC and 180 nonmalignant control subjects (healthy or with benign gastric diseases). Cases and controls will be randomly divided into a training and a testing data set at a ratio of 2:1. Plasma cfDNA will be isolated and extracted, followed by bisulfite-free low-depth whole methylome sequencing. A multidimensional model named Thorough Epigenetic Marker Integration Solution (THEMIS) will be constructed in the training data set. The model includes features such as the methylated fragment ratio, chromosomal aneuploidy of featured fragments, fragment size index, and fragment end motif. The performance of the model in distinguishing between patients with cancer and noncancer controls will then be evaluated in the testing data set. Furthermore, GC-related biomarkers, such as pepsinogen, gastrin-17, and Helicobacter pylori, will be measured for each patient, and their predictive accuracy will be assessed both independently and in combination with the THEMIS model Results: Recruitment began in November 2022 and will be ended in April 2024. As of August 2022,250 patients have been enrolled. The final data analysis is anticipated to be completed by September 2024. Conclusions: This is the first registered case-control study designed to investigate a stacked ensemble model integrating several cfDNA features generated from a bisulfite-free whole methylome sequencing assay. These features include methylation patterns, fragmentation profiles, and chromosomal copy number changes, with the aim of identifying the GC population. This study will determine whether multidimensional analysis of cfDNA will prove to be an effective strategy for distinguishing patients with GC from nonmalignant individuals within the Chinese population. We anticipate the THEMIS model will complement the standard-of-care screening and aid in identifying high-risk patients for further diagnosis. Trial Registration: ClinicalTrial.gov NCT05668910; https://www.clinicaltrials.gov/study/NCT05668910
- Open Access
- 17 April 2023
- Published by JMIR Publications Inc. in JMIR Preprints
Multidimensional Analysis of a Cell-Free DNA Whole Methylome Sequencing Assay for Early Detection of Gastric Cancer: Protocol for an Observational Case-Control Study (Preprint)
BACKGROUND Commonly used noninvasive serological indicators serve as a step before endoscope diagnosis and help identify the high-risk gastric cancer (GC) population. However, they are associated with high false positives and high false negatives. Alternative noninvasive approaches, such as cancer-related features in cell-free DNA (cfDNA) fragments, have been gradually identified and play essential roles in early cancer detection. The integrated analysis of multiple cfDNA features has enhanced detection sensitivity compared to individual features. OBJECTIVE This study aimed to develop and validate an assay based on assessing genomic-scale methylation and fragmentation profiles of plasma cfDNA for early cancer detection, thereby facilitating the early diagnosis of GC. The primary objective is to evaluate the overall specificity and sensitivity of the assay in predicting GC within the entire cohort, and subsequently within each clinical stage of GC. The secondary objective involved investigating the specificity and sensitivity of the assay in combination with possible serological indicators. METHODS This is an observational case-control study. Blood samples will be prospectively collected before gastroscopy from 180 patients with GC and 180 nonmalignant control subjects (healthy or with benign gastric diseases). Cases and controls will be randomly divided into a training and a testing data set at a ratio of 2:1. Plasma cfDNA will be isolated and extracted, followed by bisulfite-free low-depth whole methylome sequencing. A multidimensional model named Thorough Epigenetic Marker Integration Solution (THEMIS) will be constructed in the training data set. The model includes features such as the methylated fragment ratio, chromosomal aneuploidy of featured fragments, fragment size index, and fragment end motif. The performance of the model in distinguishing between patients with cancer and noncancer controls will then be evaluated in the testing data set. Furthermore, GC-related biomarkers, such as pepsinogen, gastrin-17, and Helicobacter pylori, will be measured for each patient, and their predictive accuracy will be assessed both independently and in combination with the THEMIS model RESULTS Recruitment began in November 2022 and will be ended in April 2024. As of August 2022,250 patients have been enrolled. The final data analysis is anticipated to be completed by September 2024. CONCLUSIONS This is the first registered case-control study designed to investigate a stacked ensemble model integrating several cfDNA features generated from a bisulfite-free whole methylome sequencing assay. These features include methylation patterns, fragmentation profiles, and chromosomal copy number changes, with the aim of identifying the GC population. This study will determine whether multidimensional analysis of cfDNA will prove to be an effective strategy for distinguishing patients with GC from nonmalignant individuals within the Chinese population. We anticipate the THEMIS model will complement the standard-of-care screening and aid in identifying high-risk patients for further diagnosis. CLINICALTRIAL ClinicalTrial.gov NCT05668910; https://www.clinicaltrials.gov/study/NCT05668910 INTERNATIONAL REGISTERED REPORT DERR1-10.2196/48247
- 17 April 2023
- Published by JMIR Publications Inc. in JMIR Preprints
Open AccessMultidimensional Analysis of a Cell-Free DNA Whole Methylome Sequencing Assay for Early Detection of Gastric Cancer: Protocol for an Observational Case-Control Study (Preprint)
BACKGROUND Commonly used noninvasive serological indicators serve as a step before endoscope diagnosis and help identify the high-risk gastric cancer (GC) population. However, they are associated with high false positives and high false negatives. Alternative noninvasive approaches, such as cancer-related features in cell-free DNA (cfDNA) fragments, have been gradually identified and play essential roles in early cancer detection. The integrated analysis of multiple cfDNA features has enhanced detection sensitivity compared to individual features. OBJECTIVE This study aimed to develop and validate an assay based on assessing genomic-scale methylation and fragmentation profiles of plasma cfDNA for early cancer detection, thereby facilitating the early diagnosis of GC. The primary objective is to evaluate the overall specificity and sensitivity of the assay in predicting GC within the entire cohort, and subsequently within each clinical stage of GC. The secondary objective involved investigating the specificity and sensitivity of the assay in combination with possible serological indicators. METHODS This is an observational case-control study. Blood samples will be prospectively collected before gastroscopy from 180 patients with GC and 180 nonmalignant control subjects (healthy or with benign gastric diseases). Cases and controls will be randomly divided into a training and a testing data set at a ratio of 2:1. Plasma cfDNA will be isolated and extracted, followed by bisulfite-free low-depth whole methylome sequencing. A multidimensional model named Thorough Epigenetic Marker Integration Solution (THEMIS) will be constructed in the training data set. The model includes features such as the methylated fragment ratio, chromosomal aneuploidy of featured fragments, fragment size index, and fragment end motif. The performance of the model in distinguishing between patients with cancer and noncancer controls will then be evaluated in the testing data set. Furthermore, GC-related biomarkers, such as pepsinogen, gastrin-17, and Helicobacter pylori, will be measured for each patient, and their predictive accuracy will be assessed both independently and in combination with the THEMIS model RESULTS Recruitment began in November 2022 and will be ended in April 2024. As of August 2022,250 patients have been enrolled. The final data analysis is anticipated to be completed by September 2024. CONCLUSIONS This is the first registered case-control study designed to investigate a stacked ensemble model integrating several cfDNA features generated from a bisulfite-free whole methylome sequencing assay. These features include methylation patterns, fragmentation profiles, and chromosomal copy number changes, with the aim of identifying the GC population. This study will determine whether multidimensional analysis of cfDNA will prove to be an effective strategy for distinguishing patients with GC from nonmalignant individuals within the Chinese population. We anticipate the THEMIS model will complement the standard-of-care screening and aid in identifying high-risk patients for further diagnosis. CLINICALTRIAL ClinicalTrial.gov NCT05668910; https://www.clinicaltrials.gov/study/NCT05668910 INTERNATIONAL REGISTERED REPORT DERR1-10.2196/48247
- Open Access
- 6 May 2022
- Published by Taylor & Francis in All Life
- Vol. 15 (1) , 537-546
Investigation of two ferroptosis-related molecular subtypes and biomarkers in the progression of gastric adenocarcinoma
This study aimed to investigate ferroptosis-related molecular subtypes and their potential value in gastric adenocarcinoma (GAC). Gene expression and associated clinical phenotype data were downloaded from TCGA database. Unsupervised clustering was performed to identify suitable subtypes, followed by a correlation analysis of clinical factors. Gene set variation analysis, immune infiltration, and differentially expressed genes (DEGs) were investigated between subtypes, followed by functional enrichment for DEGs. Univariate Cox regression analysis was used to screen DEGs to construct a prognostic model. Of the 53 ferroptosis-related genes identified in GAC, two ferroptosis-related molecular subtypes were further examined. These two subtypes showed significant differences in the distribution of histological grades and KEGG pathways. In addition, tumor infiltration of 10 immune cells, including Tregs and natural killer cells, was significantly different between the two subtypes. A total of 660 DEGs were identified between these two subtypes and ultimately 12 genes associated with prognosis, including GPX3, SNCG, DUSP1, and FBN1, were selected by LASSO to construct a prognostic risk model. Survival analysis showed that this model had better prognostic value. Finally, regression analysis showed that the risk score was an independent prognostic indicator of GAC. In summary, two ferroptosis-related molecular subtypes that were associated with the histological grade and tumor immune infiltration were identified. The 12 gene-based risk model had an independent value for predicting GAC prognosis.
- 6 May 2022
- Published by Taylor & Francis in All Life
- Vol. 15 (1) , 537-546
Open AccessInvestigation of two ferroptosis-related molecular subtypes and biomarkers in the progression of gastric adenocarcinoma
This study aimed to investigate ferroptosis-related molecular subtypes and their potential value in gastric adenocarcinoma (GAC). Gene expression and associated clinical phenotype data were downloaded from TCGA database. Unsupervised clustering was performed to identify suitable subtypes, followed by a correlation analysis of clinical factors. Gene set variation analysis, immune infiltration, and differentially expressed genes (DEGs) were investigated between subtypes, followed by functional enrichment for DEGs. Univariate Cox regression analysis was used to screen DEGs to construct a prognostic model. Of the 53 ferroptosis-related genes identified in GAC, two ferroptosis-related molecular subtypes were further examined. These two subtypes showed significant differences in the distribution of histological grades and KEGG pathways. In addition, tumor infiltration of 10 immune cells, including Tregs and natural killer cells, was significantly different between the two subtypes. A total of 660 DEGs were identified between these two subtypes and ultimately 12 genes associated with prognosis, including GPX3, SNCG, DUSP1, and FBN1, were selected by LASSO to construct a prognostic risk model. Survival analysis showed that this model had better prognostic value. Finally, regression analysis showed that the risk score was an independent prognostic indicator of GAC. In summary, two ferroptosis-related molecular subtypes that were associated with the histological grade and tumor immune infiltration were identified. The 12 gene-based risk model had an independent value for predicting GAC prognosis.